Heparin Inhibitor Development Service

Heparin Inhibitor Development Service

Heparin Inhibitor Development Service at CD BioGlyco

For an extensive period, CD BioGlyco has been committed to advancing the field of Glycosylation Inhibitor Development, placing special emphasis on delivering exceptional services in the realm of Glycosaminoglycan Inhibitor Development. At CD BioGlyco, our heparin inhibitor development services include but are not limited to the following directions.

  • Heparin synthase inhibitor
    Heparin synthesis begins with the synthesis of the glucosaminoglycoside core, and we design synthase inhibitors to prevent the formation of the core structure by blocking this step, such as by inhibiting the activity of enzymes including glucosyltransferase. The core structure of heparin undergoes several modification steps during synthesis, such as sulfation and hydroxyacetylation. Synthetase inhibitors can also interfere with the activity of these modifying enzymes, resulting in the inability to perform a complete modification of the core structure.
  • Sulphation inhibitors
    Sulfation is a very important step in the biosynthesis of heparin because it can confer specific biological activities and functions to the heparin molecule. We inhibit heparin production by designing sulfide inhibitors to inhibit sulfotransferase activity, interfere with the supply of sulfate donors, and regulate sulfate esterase expression.
  • Heparanase inhibitors
    We target and design heparinase inhibitors to inhibit heparin production by affecting the enzymatic activities and catabolic pathways involved in heparin production. Some inhibitors may affect the expression of relevant genes in the cell and influence the level of heparanase in the cell by regulating the expression of these genes, thus affecting the metabolism and production process of heparin.

Fig.1 Process of heparin inhibitor development. (CD BioGlyco)Fig.1 Process of heparin inhibitor development. (CD BioGlyco)


  • Heparin inhibitors are widely used to achieve clotting inhibition and to prevent diseases associated with thrombosis.
  • Heparin inhibitors can be used to control extracellular matrix biosynthesis and degradation processes, as well as the regulation of other cell signaling pathways.
  • Heparin inhibitors may have applications in the research of cancer because heparin is associated with coagulation, inflammatory, and angiogenic processes associated with tumor development and metastasis.

Fig.2 Schematic illustration of heparin derivatives and applications. (Banik, et al., 2021) Fig.2 Schematic illustration of heparin derivatives and applications. (Banik, et al., 2021)

Frequently Asked Questions

  • What is the role of heparin in the body?
    Heparin is a polysaccharide-based anticoagulant molecule synthesized primarily by cells in liver and lung tissue. It works in the body mainly by interacting with anticoagulant proteins, thereby inhibiting the clotting process and achieving anticoagulation. It mainly has the effect of inhibiting thrombin activity, inhibiting coagulation factor activity, and increasing the function of anticoagulant proteins.
  • Why develop inhibitors of heparin?
    In certain disease states, the body may produce too much heparin, leading to bleeding or impaired clotting. To minimize this risk, measures need to be taken to inhibit heparin production. In some patients who require long-term use of anticoagulants, heparin levels may need to be precisely adjusted, and sometimes the production needs to be inhibited to maintain an appropriate anticoagulant status.

CD BioGlyco uses advanced technical tools and efficient experimental methods to provide one-stop heparin inhibitor development services. We offer a variety of strategies, including techniques such as fluorescence or mass spectrometry, to validate the action and selectivity of potential inhibitors against heparin. Please feel free to contact us for more information.


  1. Banik, N.; et al. Heparin and its derivatives: challenges and advances in therapeutic biomolecules. International journal of molecular sciences. 2021, 22(19): 10524.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.